Peer-reviewedCC BY-NC-NDInternal Medicine
Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review
Abstract
Epidermal growth factor receptor (EGFR) mutations are uncommon in lung squamous cell carcinoma (SQC). However, the role of third-generation EGFR-tyrosine kinase inhibitors (TKIs) remains unclear. The present study provides a case description and a systematic literature review of 34 eligible cases. Third-generation EGFR-TKIs demonstrate superior initial responsiveness compared to earlier-generation TKIs. The efficacy of TKIs was consistent across SQC forms (including de novo or adenocarcinoma-transformed cases) and EGFR mutation types. The findings indicate that, compared with early-generation TKIs, third-generation TKIs are effective against de novo SQCs and should be considered a plausible treatment option for transformed SQCs.
Related
- Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis
- Case Report: Effective use of rituximab in children with steroid-resistant/dependent idiopathic pulmonary hemosiderosis: description of two cases and literature review
- Next-generation CDK inhibitors in HR+/HER2– breast cancer
- Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy
- The Role of Telomerase in Cellular Stress Response—Therapeutic Potential of Telomerase Inhibitors
BibTeX
@article{minematsu2026therapeutic,
title = {{Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review}},
author = {Naoto Minematsu and Yoko Imai and Toshiyuki Hirano and Tomoo Kakimoto},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.6597-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6597-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review
AU - Naoto Minematsu
AU - Yoko Imai
AU - Toshiyuki Hirano
AU - Tomoo Kakimoto
PY - 2026
DA - 2026/09/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6597-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6597-25/_article
AB - Epidermal growth factor receptor (EGFR) mutations are uncommon in lung squamous cell carcinoma (SQC). However, the role of third-generation EGFR-tyrosine kinase inhibitors (TKIs) remains unclear. The present study provides a case description and a systematic literature review of 34 eligible cases. Third-generation EGFR-TKIs demonstrate superior initial responsiveness compared to earlier-generation TKIs. The efficacy of TKIs was consistent across SQC forms (including de novo or adenocarcinoma-transformed cases) and EGFR mutation types. The findings indicate that, compared with early-generation TKIs, third-generation TKIs are effective against de novo SQCs and should be considered a plausible treatment option for transformed SQCs.
SN - 1349-7235
SN - 0918-2918
ER -